摘要
目的探讨肾络通治疗以蛋白尿为主的IgA肾病的临床疗效。方法将120例以蛋白尿为主的IgA肾病患者随机分为治疗组、对照组。在基础治疗基础上,治疗组予肾络通方,对照组予洛丁新,均治疗12个月,观察治疗前后两组疗效和中医症候积分、肾小球滤过率(GFR)、血肌酐(Scr)、24h尿蛋白定量、血浆清蛋白(ALB)等指标的变化情况。结果两组疗效比较差异有统计学意义(P<0.01),治疗后两组中医症状积分比较差异有统计学意义(P<0.01)。治疗组治疗后24h尿蛋白定量降低、ALB升高,与治疗前比较差异有统计学意义(P<0.05);与对照组比较24h尿蛋白定量、ALB差异亦均有统计学意义(P<0.05)。结论肾络通具有改善患者症状、降低蛋白尿、保护肾功能的作用。
Objective To investigate the therapeutic effects of a self-made prescription Shenluotong in treating IgA nephropathy patients with clinical presentation of prevailing proteinuria.Methods Totally 120 IgA nephropathy patients whose main clinical presentation was proteinuria were randomly divided as trial and control groups.The patients were given,besides the basic treatment,Shenluotong in the trial group,and Lotensin in the control group for 12 months.The effects,symptom scores in Chinese medicine,and indices of glomerular filtration rate （GFR）,serum creatinine （Scr）,quantity of 24 h urinary protein,and plasma albumin （ALB） were observed before and after the treatment.Results The trial group was better than the control group in effect （P〈0.01）;and so was in symptom score after treatment （P〈0.01）.After treatment the quantity of 24 h urinary protein was decreased and ALB level was increased in the trial group （P〈0.05）;and there were significant differences as compared with the control group （P〈0.05）.Conclusion The Shenluotong can improve the symptom,reduce proteinuria,and protect renal function for IgA nephropathy patients.
出处
《中国全科医学》
CAS
CSCD
北大核心
2010年第7期781-783,共3页
Chinese General Practice
基金
河北省中医药管理局资助课题(05033)
关键词
IGA肾病
肾络通
蛋白尿
IgA nephropathy
Shenluotong
Proteinuria
作者简介
通讯作者：潘莉，050091河北省石家庄市，河北医科大学中西医结合学院；E—mail：panli-123456@163．com
